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A universal bioluminescence resonance energy
transfer sensor design enables high-sensitivity
screening of GPCR activation dynamics
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G-protein-coupled receptors (GPCRs) represent one of the most important classes of drug
targets. The discovery of new GCPR therapeutics would greatly benefit from the development
of a generalizable high-throughput assay to directly monitor their activation or de-activation.
Here we screened a variety of labels inserted into the third intracellular loop and the C-
terminus of the α2A-adrenergic receptor and used fluorescence (FRET) and bioluminescence
resonance energy transfer (BRET) to monitor ligand-binding and activation dynamics. We
then developed a universal intramolecular BRET receptor sensor design to quantify efficacy
and potency of GPCR ligands in intact cells and real time. We demonstrate the transferability
of the sensor design by cloning β2-adrenergic and PTH1-receptor BRET sensors and mon-
itored their efficacy and potency. For all biosensors, the Z factors were well above
0.5 showing the suitability of such design for microtiter plate assays. This technology will aid
the identification of novel types of GPCR ligands.
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G-protein-coupled receptors (GPCRs) constitute the largestand the most diverse group of membrane receptors ineukaryotes. They play a role in a plethora of cellular
processes. Despite their functional diversity, they share a similar
molecular architecture of seven transmembrane helices and a
conserved mechanism of activation. Binding of agonist ligands to
their cognate receptor leads to a change in the arrangement of
distinct transmembrane helices, and a pronounced outward
movement of helix 6 (up to 14 Å)1, which is then propagated to
the third intracellular loop that connects helix 5 with 6, thus
enabling the engagement of several downstream signaling path-
ways, most importantly the activation of G-proteins. We pre-
viously demonstrated that such ligand-induced conformational
changes can be visualized in living cells by Förster Resonance
Energy Transfer (FRET). The average distance between the third
intracellular loop and the C-terminus of receptors (e.g., β2AR 6.2
nm)2 is within the range addressable by FRET (2.4–7.2 nm)3.
Therefore, tagging these conformationally sensitive sites with
fluorescent donors and acceptors permits the recording of
receptor activation as a change in energy transfer between these
chromophores. Following this principle, a series of intramolecular
FRET-based GPCR-biosensors have been generated, notably for
the α2A-adrenergic receptor (α2AAR), employing the fluorescent
proteins CFP and YFP (α2AARCFP/YFP)4,5 or CFP with the small
Fluorescein Arsenical Hairpin Binder (FlAsH) as fluorophores6.
These FRET-based GPCR biosensors have become widely used
tools7 and represent the most direct unbiased way to determine
the effects of ligands on a given receptor. Their employment has
helped to elucidate several aspects of receptor pharmacology and
kinetics8. However, the combination of donor and acceptor
fluorophores used so far suffers from a low signal-to-noise ratio
and high fluorescence background which limits their use to
single-cell experiments, slowing down the characterization of new
pharmacological compounds as GPCR-directed therapeutics.
More recently, Bioluminescence Resonance Energy Transfer
(BRET) has been tested as an alternative approach to monitor the
conformational change of receptors. BRET occurs between
proximally situated donor–acceptor pairs (1.6–8.5 nm)9, but here
a light emitting enzyme luciferase is used as a donor, sidestepping
many of the deficiencies associated with direct illumination of the
sample. Earlier attempts to generate intramolecular GPCR BRET-
based biosensors employing Renilla Luciferase as a donor in
combination with GFP or FlAsH as acceptor showed poor
agonist-induced BRET changes10–13.
Despite the many efforts in optimizing the way in which we
study GPCRs and a plethora of methods to assess ligand binding
or downstream signaling, the lack of a generalizable assay to
monitor directly in living cells receptor activation or de-activation
in a format suitable for high-throughput screening is slowing
down the progress in discovering new GPCR therapeutics. In the
present study, we therefore set out to permutate the well-
characterized FRET-based biosensor α2AARCFP/YFP in order to
develop a universal and versatile sensor design to reach the
stringent requirements of monitoring receptor conformational
dynamics in intact cells in microtiter plates.
Preserving the fluorophore insertion sites in the third intra-
cellular loop and C- terminus, we investigated whether combining
different donors and acceptors would improve the transfer of
energy to enable the visualization of the receptor’s conformational
changes in microtiter plates. Among the 10 FRET-based and the
11 BRET-based α2AAR biosensors generated in this study, the
highest amplitude in the signals upon norepinephrine stimulation
was recorded with the BRET-based α2AAR biosensors combining
NanoLuc14 luciferase as the donor and the self-labeling protein tag
Halo labeled with the HaloTag dye NanoBRET 618 as the
acceptor. The EC50-values calculated for these BRET experiments
were in line with binding affinities, demonstrating that the
developed BRET biosensor α2AARNluc/Halo assay faithfully reports
ligand affinities. This feature was conserved also for a β2-adre-
nergic and a PTH1 receptor BRET-based biosensors. Also for
these two receptors, the agonist-induced BRET changes were in
line with the binding data suggesting that our receptor biosensor
design is a generalizable design that may be use in lieu of the
endogenous receptor to determine efficacy and potency of ligands.
To assess the applicability of the biosensor design to microtiter
plate and its scalability, we performed for each receptor a Z-factor
analysis15 to quantify the quality and reproducibility of the assays.
For all receptors analyzed, the Z-factor was well above 0.5—which
characterizes an excellent assay suitable to be used in microtiter
plates. We propose that this technology will speed the character-
ization of new pharmacological compounds acting at GPCRs.
Results
Dynamic range of FRET- and BRET-based α2AAR biosensors.
With the goal of generating a GPCR biosensor design to monitor
receptor activation in microtiter plates, we permutated the well-
characterized FRET-based biosensor α2AARCFP/YFP. We preserved
the fluorophore insertion sites in the third intracellular loop and
C-terminus (Fig. 1a) but we substituted the original YFP with its
brighter variant cpVenus or with self-labeling protein tags: SNAP
(α2AARCFP/SNAP; 20 kDa)16 or Halo (α2AARCFP/Halo; 36 kDa)17.
Both of these tags can be labeled covalently with exogenous cell-
permeable fluorescent dyes. Their diverse emission and excitation
peaks (Fig. 1b, Supplementary Fig. 1), degrees of spectral overlap
with the donor emission (CFP) and photophysical properties
impacted the FRET behavior that we observed, allowing us to
optimize our approach using a modular fluorophore within the
receptor chassis. In this optimization phase, HEK cells were
transiently transfected with the different α2AAR biosensors and,
after specific labeling, experiments were performed in 96-well
plates (Fig. 1c). Each FRET-based pair exhibited a different degree
of basal transfer of energy—as demonstrated by their respective
FRET emission spectra (Fig. 1d). However, only five of the ten
FRET-based pairs tested showed a detectable agonist-induced
change in FRET (ΔFRET%) that did not exceed 5% when sti-
mulated by the full agonist norepinephrine (100 µM) (Fig. 1e).
With the goal of obtaining a higher dynamic range, we tested
BRET as possibly more sensitive approach. Here, we used the
relatively small-sized NanoLuc14 luciferase (19 kDa; Nluc) that
possesses, in presence of its substrate (furimazine), a narrow
bioluminescence spectrum, high brightness, and physical stability.
We generated 11 BRET-based α2AAR biosensors combining
the donor Nluc with fluorescent proteins of different color from
yellow (cpVenus) to orange-red (mCherry; TagRFP), or with the
self-labeling Halo or SNAP tags. Applying the workflow
developed above (Fig. 1c), we tested the ability of the α2AAR
BRET biosensors to report effects of the full agonist norepi-
nephrine in microtiter plate format. All the tested receptor BRET-
sensors exhibited a basal energy transfer (Fig. 1f), while the
activation of the receptor induced by norepinephrine at a
concentration of 100 μM was detectable in seven of them. The
highest amplitude was recorded for Nluc combined with the
HaloTag dye NanoBRET 61818 (α2A-ARNluc/Halo618; ΔBRET %=
8.15 ± 0.72) (Fig. 1g)—about two-fold higher than all other 20
FRET- and BRET-biosensors tested. No further improvement in
the amplitude of ΔBRET was obtained by swapping the positions
of donor and acceptor (Supplementary Fig. 2).
Pharmacology of the α2A-ARNluc/Halo618 BRET-based biosensor.
We then sought to ascertain that the α2AARNluc/Halo618 faithfully
recorded efficacies and potencies of a panel of known α2AAR
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ligands (Supplementary Table 1). We created a cell line stably
expressing this biosensor, and after optimizing the assay condi-
tions (Supplementary Fig. 3), we measured ligand-induced BRET-
responses. Stimulation with the full agonist norepinephrine (100
μM) and the inverse agonist yohimbine (100 µM) induced
changes in BRET with opposite directions (Fig. 2a; agonist:
positive ΔBRET blue line; inverse agonist: negative ΔBRET black
line)—mirroring the opposite pharmacological effect exerted at
the receptor level. The changes in BRET evoked by both ligands
were fast, reaching a plateau 120 s after their injection, and
remained stable for more than 30 min (Supplementary Fig. 4).
The injection of the antagonist phentolamine (1 µM) reverted
the effect of norepinephrine (Fig. 2a; red line), demonstrating
the applicability of the biosensor to monitor inactivation kinetics.
A panel of seven additional ligands triggered responses ranging
between the two extremes, norepinephrine and yohimbine,
and compatible with their known efficacies as full, partial,
or inverse agonists (Fig. 2b, Supplementary Table 1). Full
concentration–response curves were performed for all ten com-
pounds (Fig. 2c). Radioligand binding experiments demonstrated
that the BRET biosensor α2AARNluc/Halo had binding affinities
(pKi-values) similar to the wild-type receptor (Supplementary
Table 2), and they correlate with the measured EC50-values
(Supplementary Table 3), indicating that our assay faithfully
reports ligand affinities. Interestingly, for agonists these EC50-
values were similar to the high-affinity component of the com-
petition curves (pKH) generally assumed to represent the recep-
tor/G-protein complex19. This indicates some constitutive activity
of the α2AARNluc/Halo biosensor and its interaction with endo-
genous G-proteins. The relative BRET-change induced by neutral
ligands and also the characterization of G-protein activation
(Supplementary Fig. 5) demonstrated some constitutive activity of
the biosensor. Such constitutive activity, not seen with analogous
GFP-based sensors20, might be due to the larger size of the tags
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Fig. 1 Evaluation of intramolecular FRET and BRET α2A-adrenergic receptor biosensors. a Schematic of the biosensor. b Emission peaks of chromophores. c
Workflow. d FRET emission spectra of the CFP-label alone or with fluorescent acceptors (each N= 1). e FRET changes (%) induced by norepinephrine
normalized for buffer (YFP: N= 7, cpVenus173: N= 4, diAcFAM: N= 6, Oregon Green: N= 5, R110 Direct: N= 3,TMR Direct: N= 6, NanoBRET 618: N= 6,
505-star: N= 5, TMR-star: N= 5, 647SiR: N= 4). f BRET emission spectra of the NanoLuc-label alone or with fluorescent acceptors (each N= 1). g BRET
changes (%) induced by norepinephrine normalized for buffer (cpVenus173: N= 7, TagRFP: N= 4, mCherry: N= 4, diAcFAM: N= 3, Oregon Green: N= 3,
R110 Direct: N= 3, TMR Direct: N= 3, NanoBRET 618: N= 7, 505-star: N= 3, TMR-star: N= 5, 647SiR: N= 5). Data in e and g show box and whisker
plots. Difference was analyzed by two-way ANOVA followed by Bonferroni post hoc test. *p≤ 0.05 vs. buffer
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employed that might separate helices 5 and 6, which would shift
the receptor to a more active state. However, this effect did not
change the expected order of efficacies of the various ligands and
even facilitated the characterization of both, inverse agonists and
antagonists. Overall, these data indicate that the intramolecular
α2AARNluc/Halo618 BRET-biosensor faithfully reports the activa-
tion state of the α2AAR in 96-well plates.
Microtiter plate suitability of the α2AARNluc/Halo618. To validate
the suitability of the novel BRET-based biosensor α2AARNluc/
Halo618 to monitor receptor conformation in microtiter plate
format, we performed the Z-factor analysis15 to quantify the
quality and reproducibility of the assay. In this analysis, values Z
< 0 defines unusable assays, Z= 1 approximates a “perfect” assay,
and Z ≥ 0.5 characterizes an excellent assay. Compared to the
original α2AARCFP/YFP, classified as unusable (Z= –1.60 ± 0.97;
Fig. 2d, f), α2AARNluc/Halo618 yielded an excellent assay (Z= 0.65
± 0.01; Fig. 2e, f) that was stable for more than 20 min (Fig. 2g).
β2-adrenergic receptor BRET-biosensor (β2ARNluc/Halo618). To
demonstrate the transferability of the BRETNluc/Halo618 as a gen-
eral design to pharmacologically profile any GPCR, we generated
an analogous β2-adrenergic receptor biosensor (β2ARNluc/Halo618)
and measured efficacy and potency of different ligands in
microtiter plate format. The β2ARNluc/Halo618 biosensor showed
signaling activity similar to the wild-type receptor (Supplemen-
tary Fig. 6a–c). Full agonist stimulation induced a change in
BRET opposite to that of an inverse agonist, while the
amplitudes for antagonists and partial agonists were intermediate
(Fig. 3a), demonstrating that the ability of reporting the efficacy
of ligands was preserved. The EC50-values obtained from
concentration–response curves for the full agonist epinephrine,
the inverse agonist ICI 118,551 and the neutral antagonist car-
vedilol (Fig. 3b), were similar to data obtained by radioligand
binding assay (Supplementary Table 4), demonstrating the β2AR
BRET-based biosensor was reporting wild-type affinity and effi-
cacy. Interestingly, we found that norepinephrine, usually con-
sidered a full agonist when monitored at the second messenger
level21 (cAMP), induced only a partial conformational change of
β2ARNluc/Halo618—in line with other conformational studies22,23.
Our data would also support the new evidence suggesting that UK
14,304 behaves as a partial24 more than a full agonist. This
demonstrates that BRET-based biosensors are a powerful
unbiased approach, since they bypass the effect of signal ampli-
fication and receptor reserve. Again, the Z-factor of ≈ 0.8 was
greatly improved compared to the earlier FRET β2AR-biosensor
and indicated the suitability for high-throughput screening
(Fig. 3c; Supplementary Fig. 8)
Parathyroid hormone receptor 1 BRET-biosensor
(PTHR1Nluc/Halo618). To further substantiate the transferability
of the BRETNluc/Halo618 sensor design, we devised an analogous
class B parathyroid hormone receptor 1 (PTHR1) BRET-
biosensor (PTHR1Nluc/Halo618). Again, this biosensor retained
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signaling activity (Supplementary Fig. 6d–f), efficacy (Fig. 3d) and
affinity (Fig. 3e) similar to the wild-type receptors (Supplemen-
tary Table 5) for the analyzed peptides.
Application of the full agonist PTH(1-34) evoked a ≈10%
change in BRET. Antagonists had no detectable effects (Fig. 3d),
but retained their ability of inhibiting receptor activation in
competition experiments (Supplementary Fig. 7). In contrast to
the α2AAR and β2AR, no inverse agonists are available for the
PTHR1 that might cause effects opposite to those of PTH(1-34).
The Z-factor for PTHR1Nluc/Halo618 (0.52 ± 0.02) demonstrated
that also this BRET-biosensor was suitable for high-throughput
screening (Fig. 3f; Supplementary Fig. 8).
Discussion
Taken together, we have developed a universal sensor design for
GPCRs that retains the signaling capacity of the receptors,
resolves both efficacy and potency of ligands, and works in intact
cells and in real time in a microtiter plate format. In a single
assay, this approach offers the analysis of activation/de-activation
kinetics, potency and direct efficacy–which makes it a rapid and
high content screening approach. The throughput of this assay
essentially depends on the equipment available for pipetting and
plate reading. Under optimal conditions, it depends only on the
time required to read the plate before and after addition of
compounds, while under the most basic conditions, the time
required for a single plate would encompass the times required
for the basal read, addition of compounds, and a second read. If
the labeling procedure is carried out in serum- and phenol red-
free medium, then no washing step is required.
As any optical detection method, the readout of our BRET-
based receptor biosensor may be impaired by molecules that
interfere with the absorption properties; bind to the energy donor
or acceptor interfering with their emission properties; and com-
pete with the substrate, causing inhibition of the luciferase25. The
chemical evaluation of compounds of a screening library can help
discriminating false positives. Appropriate controls for these
issues therefore need to be included in such a screening approach.
An advantage of our receptor biosensor is that the tags are
localized intracellularly, which limits their susceptibility to cell
permeable compounds.
To the best of our knowledge, this generalizable design offers
the first possibility to upscale the study of receptor activation and
deactivation - which represents the most direct and unbiased way
to estimate the effect of any chemical entity on receptors of
interest, facilitating the discovery of new therapeutic compounds.
These GPCR biosensors should prove useful in determining
ligand properties at known GPCRs and in elucidating the binding
properties of orphan receptors. Furthermore, their high sensitivity
may allow their use to monitor GPCR activation in situ using new
knock-in technologies26.
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Methods
cDNA constructs. The FRET sensor α2AARCFP/YFP4 was used as starting construct
to generate the various α2A-adrenergic receptor FRET and BRET sensors
(α2AARdonor/acceptor) described in this study. The donors (CFP or Nluc) were fused
to Val461 at the C-terminus while all acceptors tested were placed in the third
intracellular loop between Ala250 and Ser371. The BRET-based β2-adrenergic
receptor biosensor β2ARNluc/Halo was cloned starting from the previously described
FRET version22 introducing HaloTag in the third intracellular loop between
Asp251 and Gly252 and Nluc in the C-terminus at Glu369. The BRET sensor for
the parathyroid hormone receptor (PTHR1) was cloned starting from the pre-
viously described FRET version4. HaloTag was inserted in the third intracellular
loop between Gly395 and Arg396 and Nluc was fused to Gly497 of the C terminus.
All tag exchanges were performed employing established PCR strategies and
restriction and ligation enzymes. Constructs were cloned into a pcDNA3 vector
and verified by sequencing.
Plasmids. cDNA encoding the fluorescent protein cpVenus173 was amplified from
the Gαi2-sensor v2.027. The SNAPtag sequence was amplified using a SNAPtag-
GABAB1 template kindly provided by J.P. Pin (Institut de Génomique Fonction-
nelle, Montpellier, France)28. Sequences encoding TagRFP (pTagRFP-C vector)
and mCherry were purchased from Evrogen and Addgene, respectively. cDNA
encoding HaloTag (pFC14K HaloTag® CMV Flexi® Vector) and NanoLuciferase
(pFC32K Nluc CMV-neo Flexi® Vector) were purchased from Promega. Gαi2-
FRET27 sensor was kindly provided by J. Goedhart (Section Molecular Cytology,
University of Amsterdam, Amsterdam, The Netherlands), the H187-EPAC-FRET
sensor29 was kindly provided by K. Jalink (The Netherlands Cancer Institute,
Amsterdam, The Netherlands).
Reagents. (−)-Epinephrine, L-(−)-norepinephrine (+)-bitartrate salt mono-
hydrate, UK 14,304, dopamine hydrochloride, (±)-octopamine hydrochloride,
clonidine hydrochloride, tyramine hydrochloride, phentolamine hydrochloride,
yohimbine hydrochloride, isoprenaline hydrochloride, formoterol fumarate dihy-
drate, terbutaline hemisulfate salt, salmeterol xinofoate, salbutamol hemisulfate
salt, metoprolol tartrate, (±)-propranolol hydrochloride, ICI 118,551 hydro-
chloride, labetalol hydrochloride, carvedilol, GTP, poly-D-lysine, G-418 and the
fluorescent monoclonal antibody Anti-Flag® M2-Cy3 and Millipore glass-fiber
filters for radioligand saturation binding were from Sigma-Aldrich. [3H]RX821002
was purchased from Hartmann Analytic. The HA-tag monoclonal antibody
(16B12) Alexa Fluor 488 was from ThermoFisher Scientific. Oxymetazoline
hydrochloride was purchased from Tocris. The peptide ligands PTH(1-34) (catalog
number: H-4835), PTH(7-34) (catalog number: N-1110), (dw)-PTH(7-34) (catalog
number: H-9115), PTHrP(1-34) (H-6630), PTH(1-31) (catalog number: H-3408)
and PTH(3-34) (catalog number: H-3088) were from BACHEM. All HaloTag
fluorescent dyes were purchased from Promega. SNAP fluorescent dyes were from
NEB. White-wall, white bottomed and black-wall, black-bottomed 96-well plates
were purchased from Brand. MultiScreen® Filter plates for radioligand competition
binding were from Millipore.
Cell culture and transfection. HEK-TSA cells used for transient expression of
constructs, were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) sup-
plemented with 2 mM glutamine, 10% fetal calf serum, 0.1 mg mL−1 streptomycin,
and 100 units per mL penicillin at 37 °C with 5% CO2. HEK293 cells were used for
the development of stable BRET sensor cell lines. Cells grown in 100 mm dishes
were transfected at a confluence of 50–70% with 5 µg of DNA using Effectene
Transfection Reagent Kit (Qiagen) according to the manufacturer’s instructions.
Transfected clones were selected with 600 μg mL−1 of G-418 and clonal lines were
maintained in DMEM supplemented with 200 μg mL−1 G-418, 2 mM glutamine,
10% fetal calf serum, 0.1 mg mL−1 streptomycin, and 100 units per mL penicillin at
37 °C with 5% CO2.
Transient transfection and plating. For transient expression of the sensors, 1.5 ×
106 HEK-TSA cells were seeded onto a 55 mm dish and transfected the day after
with 2 µg of plasmids encoding the biosensors using Effectene Transfection
Reagent (Qiagen) according to the manufacturer’s protocol. In case two different
plasmids were co-transfected, 4 µg was used as total amount of DNA in a 1:1 ratio
of the two plasmids. Twenty-four hours after transfection, cells were transferred to
poly-D-lysine pre-coated black-wall, black-bottomed (FRET experiments) or white-
wall, white-bottomed (BRET experiments) 96-well plates at a density of 50,000
(FRET) or 20,000 (BRET) cells per well.
Fluorescence labeling of FRET and BRET acceptors. Labeling with all dyes was
performed at 37 °C and 5% CO2 in 96-well plates. All dyes were dissolved in
DMEM. HaloTag® diAcFAM (1 µM), HaloTag® Oregon Green® (1 µM), SNAP-cell
505-Star (10 µM), SNAP-cell TMR-Star (3 µM) and SNAP-cell 647SiR (3 µM) were
incubated for 30 min 48 h after transfections. Excessive dye was washed out three
times followed by incubation with fresh DMEM for additional 30 min (37 °C and
5% CO2). HaloTag® R110Direct, HaloTag® TMRDirect and HaloTag® NanoBRET
618 required overnight labeling at a concentration of 100 nM. A minimum of 4
wells remained unlabeled to serve as correction for donor bleedthrough (unlabeled
control).
Measurement of fluorescence excitation and emission spectra. HEK-TSA cells
were transfected with different BRET based α2AAR biosensors and labeled as
described above, without substrate, in order to read only the emission and exci-
tation spectra of the different acceptors. YFP and CFP spectra were collected using
the FRET α2AARCFP/Halo and α2AARYFP/Halo biosensors without HaloTag labeling.
All spectra were measured in buffer (2 mM HEPES, 28 mM NaCl, 1.08 mM KCl,
0.2 mM MgCl2, 0.4 mM CaCl2, pH 7.3) with 2 nm resolution from 400 to 700 nm
using a CLARIOstar plate reader (BMG). Spectra are expressed as a percentage of
the respective maximal excitation or emission peak.
Measurement of FRET and BRET emission spectra. HEK-TSA cells were
transfected and labeled as described above. Emission spectra were recorded in
buffer with 2 nm resolution from 400 to 700 nm upon donor excitation at 420 nm
(FRET sensors) or addition of 1:1000 furimazine dilution (BRET) using a CLAR-
IOstar plate reader (BMG). Spectra are expressed as a percentage of the maximal
donor emission peak.
FRET measurements. Cells expressing the FRET sensors were washed to sub-
stitute the DMEM with the experimental buffer. Basal FRET ratio was measured in
90 µL buffer. Subsequently, 10 µL of 10-fold ligand solution or buffer (negative
control) was applied to each well and the stimulated FRET ratio was recorded. All
FRET experiments were conducted at 37 °C with a Synergy Neo2 plate reader
(BioTEK) equipped with 420/50 nm excitation and 485/20 nm emission filters for
CFP. Acceptor emission of YFP, HaloTag® R110, HaloTag® diAcFAM, HaloTag®
Oregon Green® and SNAP-cell 505-Star were detected with a 540/25 nm (FRET)
filter. To measure the emission of HaloTag® TMR-Direct and SNAP-cell TMR-Star
a 590/35 nm filter was used. Emission of HaloTag® NanoBRET 618 and SNAP-cell
647SiR were detected with a 620/15 nm and 680/20 nm filter, respectively. Fifty
excitation flashes were applied per data point.
BRET measurements. Cells transiently or stably expressing the BRET-biosensors
were washed to substitute DMEM with the experimental buffer and incubated with
substrate (90 µL of 1:1000 for β2ARNluc/Halo618 and PTHR1 Nluc/Halo618; 1:4000 for
α2AAR Nluc/Halo618) for 2–5 min at 37 °C to allow for substrate diffusion and the
basal BRET ratio was measured. Following this, 10 µL of 10-fold ligand solution or
buffer was applied to each well and the stimulated BRET ratio was recorded. To
reduce the fluctuation of the BRET ratio in Z-factor experiments, seven individual
BRET ratios within 5 min were measured and averaged before and after ligand
addition.
BRET experiments were performed at 37 °C with a GloMAX Discover
(Promega) or Synergy Neo2 (BioTEK) plate reader equipped with a 460/40 nm
filter to select the NanoLuc emission. For cpVenus173, HaloTag® R110, HaloTag®
diAcFAM, HaloTag® Oregon Green® and SNAP-cell 505-Star a 520/20 nm (BRET)
filter was used to select the acceptor emission peaks. TagRFP, HaloTag® TMR-
Direct and SNAP-cell TMR-Star emissions were detected with a 530 nm long pass
filter. For HaloTag® NanoBRET 618 a 620/20 nm filter was used and a 600 nm long
pass filter was applied for the BRET acceptors mCherry and SNAP-cell 647SiR. The
integration time per data point was set to 0.3 s.
Experiments with higher temporal resolution were performed employing the
Synergy Neo2 (BioTEK) plate reader, which is equipped with injectors and has a
faster acquisition time. Data were acquired in well-mode, the acquisition interval
was set to 1 s and the integration time to 0.3 s. After acquisition of baseline for 180
s, 10 µL of solution with or without ligand (buffer control) were injected with a
speed of 225 µL s−1 (delivery time= 44 ms) and the signal was recorded for
180–360 s.
Receptor staining. Cells were co-transfected with FRET-based sensors to monitor
downstream signaling and the wild type or the BRET-biosensor receptor as
described above. Staining of the plasma membrane portion of the receptors was
evaluated using a cell-impermeable anti HA-tag conjugated with AlexaFluor594
(Anti-HA-AlexaFluor594 ThermoFischer) or Anti-Flag® M2 conjugated with Cy3
(Anti-Flag® M2 Cy3, Sigma). The fluorescent antibodies were diluted in DMEM to
a concentration of 10 µg mL−1 and incubated for 1 h at 37 °C in the 96-well plates.
Subsequently, cells were rinsed three times and incubated additional 30 min with
fresh DMEM.
Subsequently, the emission intensity of HEK-TSA cells were measured using the
Synergy Neo2 plate reader. Therefore, cells stained with Anti-Flag® M2 Cy3
(β2ARNLuc/Halo or β2AR) were excited using a 540/20 nm excitation and the
emission intensity was recorded using 590/35 nm emission filter. Fluorescence
intensities of HEK-TSA cells stained with Anti-HA-AlexaFluor594 were measured
using a 590/20 nm (excitation)–620/15 nm (emission) filter combination.
Expression levels of Gαi2-FRET and H187-EPAC-FRET sensor. The Synergy
Neo2 plate reader was employed to assess the expression levels of the downstream
sensors (Gαi2-FRET and H187-EPAC-FRET sensor). Therefore, the FRET
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acceptors (cpVenus173 and tandem cpVenus173) were directly excited using a 500/
20 nm excitation filter. Emission intensities were detected with a 540/20 nm filter.
Membrane preparations. Membranes expressing wild-type α2AAR (α2AAR-wt)
were harvested from HEK-TSA cells grown in 15 cm dishes, 48 h after transfection.
Membranes expressing the BRET-based α2AAR sensor (α2AARNluc/Halo) were
obtained from HEK293 stably expressing the sensor. Cells were detached from the
dishes with a cell scraper and suspended in Tris buffer (5 mM Tris, 2 mM EDTA,
pH 7.4). After centrifugation for 10 min at 1000 × g, cells were re-suspended in
buffer 1 (20 mM HEPES, 10 mM EDTA, PBS, pH 7.4) and homogenized using
twice Ultraturax for 15 s. The suspension was centrifuged for 10 min at 3200 × g.
The resulting supernatant was further centrifuged for 45 min at 37,000 × g and 4 °
C. The pellet was resuspended and the last two centrifugation steps were repeated.
The pellet was then suspended in binding buffer (50 mM Tris, 100 mM NaCl, 3
mM MgCl2, pH 7.4) and the amount of total membrane protein was measured
using the Pierce BCA Protein Assay Kit according to the manufacturer’s
instructions.
Radioligand binding. Total radioligand binding was assessed by incubating 5 µg of
membrane protein with different concentrations (0.04–12 nM) of the antagonist
α2AAR radioligand [3H]RX821002. To define unspecific binding, 20 µM phento-
lamine was added. Competition binding was performed by incubating 2 µg
membrane protein with 0.3–2.0 nM [3H]RX821002 and increasing concentrations
of the different α2AAR ligands in the presence (=low affinity state for agonists) and
absence (=high-affinity state for agonists) of 10 µM GTP. Following incubation for
1 h at room temperature, membranes were transferred to Millipore glass-fiber
filters via vacuum filtration. These filters were incubated with scintillation cocktail
and membrane-bound radioactivity was measured with a scintillation counter.
Data analysis and statistics. FRET and BRET ratios before (Ratiobasal) and after
ligand or buffer application (Ratiostim) were defined as acceptor emission/donor
emission and corrected for donor bleedthrough into the acceptor channel by
subtracting the averaged ratio of the unlabeled control (UC). For cells expressing
biosensors with a fluorescent protein as acceptor, the averaged UC ratio of the
analogous HaloTag construct was considered for bleedthrough correction.
To quantify the ligand induced conformational change, ΔFRET or ΔBRET was
calculated for each well as a percent over basal (((Ratiostim− Ratiobasal)/
Ratiobasal) × 100) and subtracted by the averaged ΔFRET or ΔBRET of buffer.
Z-factors expressing the high-throughput suitability were calculated with the
following equation:
Z ¼ 1 3σS þ 3σCð Þ
μS  μC
 
where σs and σc are the standard deviations of ΔFRET or ΔBRET. μS and μC express
the mean of ΔFRET or ΔBRET values of positive and negative control, respectively.
If the positive control induced a decrease in the energy transfer (negative ΔRET as
for α2AARCFP/YFP, β2ARNanoLuc/Halo618, PTHR1NanoLuc/Halo618, PTHR1CFP/YFP) the
denominator in equation is inverted (μC− μS). As a positive control, we defined
epinephrine for the α2AAR- and β2AR-sensors and PTH(1-34) for PTHR1 sensors.
Buffer was used as a negative control in all Z factor experiments.
For simplicity, all agonist-induced RET changes were consistently plotted as
ascending curves or bars. Therefore, y-axes in all figures were inverted if agonists
for the respective biosensor induced a reduction of the ratio.
Data were analyzed using Prism 5.0 software (GraphPad) and expressed as
mean ± s.e.m. Data from concentration–response experiments were fitted using a
mono-exponential curve four-parameter fit. Radioactivity values from binding
experiments were analyzed using a one-site fitting model if GTP was added prior
the experiment. Data from competition-binding experiments without exogenously
added GTP were first analyzed for the statistically preferred fitting model applying
extra-sum-of squares F-test comparing a one-component vs. two-component fit.
Superiority of the two-component model was confirmed for all agonists (partial or
full) tested. The two-component fit was then conducted with the fraction of the
high-affinity component (RH) fixed to 0.58 which is the mean RH of all data where
this model was applied. Statistical differences were evaluated using one-way
ANOVA test followed by Bonferroni multiple comparison, Student’s t-test or
extra-sum-of squares F-test. Differences were considered significant for values of p
< 0.05.
Data availability. The datasets generated during and/or analysed during the
current study are available at the homepage of the Institute of Pharmacology
and Toxicology http://www.pharmakologie.uni-wuerzburg.de/fileadmin/03250100/
user_upload/Schihada_et_al._CommsBio_2018_-_Figure_1-3.zip
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